195 stocks · 29 setups today · as of Nov 18, 2026
Each stock once, in its most actionable state, ranked as on the breakout page. Chart data is 15-minute delayed; setups update after the close. For information only, not a recommendation.
| Stock | Industry | Tier | Watchlist | |||||
|---|---|---|---|---|---|---|---|---|
ROIVRoivant Sciences Ltd. | Holding +0.6% · day 8 | +0.05% | $38.73 | 90 | $27.98B | Immunology Biotech | Major | |
TGTXTG Therapeutics, Inc. | Holding +4.0% · day 6 | +5.44% | $66.12 | 97 | $10.12B | Immunology Biotech | Core | |
BIIBBiogen Inc. | Closed below pivot -0.3% | +0.25% | $251.41 | 90 | $37.15B | Neuroscience Biotech | Core | |
VTRSViatris Inc. | Near pivot -2.2% | -0.83% | $20.28 | 92 | $23.62B | Specialty & Generic Drugs | Core | |
ASNDAscendis Pharma A/S | Near pivot -3.0% | -0.32% | $270.33 | 78 | $16.79B | Rare Disease Biotech | Core | |
LLYEli Lilly and Company | — | -2.33% | $1,382.54 | 88 | $1.3T | Big Pharma | Core | |
JNJJohnson & Johnson | — | -2.15% | $272.70 | 79 | $656.45B | Big Pharma | Core | |
ABBVAbbVie Inc. | — | -2.34% | $285.96 | 85 | $505.23B | Big Pharma | Core | |
MRKMerck & Co., Inc. | — | -3.90% | $137.78 | 79 | $340.29B | Big Pharma | Core | |
NVSNovartis AG | — | -2.46% | $155.21 | 66 | $295.01B | Big Pharma | Core | |
AZNAstraZeneca PLC | — | -1.93% | $178.76 | 61 | $278.87B | Big Pharma | Core | |
AMGNAmgen Inc. | — | -3.07% | $443.89 | 82 | $239.57B | Big Pharma | Core | |
GILDGilead Sciences, Inc. | — | -0.75% | $168.98 | 86 | $209.8B | Vaccines & Infectious Disease | Core | |
NVONovo Nordisk A/S | — | -3.12% | $39.43 | 41 | $175.09B | Big Pharma | Core | |
PFEPfizer Inc. | — | -1.44% | $28.06 | 69 | $159.93B | Big Pharma | Core | |
VRTXVertex Pharmaceuticals Incorporated | — | +0.42% | $536.45 | 77 | $136.15B | Rare Disease Biotech | Core | |
BMYBristol-Myers Squibb Company | — | -2.92% | $59.56 | 64 | $121.63B | Big Pharma | Core | |
SNYSanofi | — | -0.86% | $47.12 | 62 | $113.14B | Big Pharma | Core | |
REGNRegeneron Pharmaceuticals, Inc. | — | -1.28% | $945.53 | 88 | $97.41B | Immunology Biotech | Core | |
GSKGSK plc | — | -1.34% | $48.58 | 51 | $97.33B | Big Pharma | Core | |
MRNAModerna, Inc. | — | -4.84% | $196.79 | 99 | $78.08B | Vaccines & Infectious Disease | Core | |
TAKTakeda Pharmaceutical Company Limited | — | -1.71% | $21.27 | 88 | $67.67B | Big Pharma | Core | |
ARGXargenx SE | — | -0.66% | $941.25 | 64 | $61.07B | Immunology Biotech | Core | |
TEVATeva Pharmaceutical Industries Limited | — | -0.92% | $42.23 | 89 | $49.96B | Specialty & Generic Drugs | Core | |
ONCBeOne Medicines AG | — | -2.34% | $403.60 | 79 | $43.13B | Oncology Biotech | Core | |
RVMDRevolution Medicines, Inc. | — | -1.76% | $159.82 | 89 | $33.98B | Oncology Biotech | Major | |
GMABGenmab A/S | — | -1.91% | $50.97 | 96 | $31.29B | Oncology Biotech | Core | |
INSMInsmed Incorporated | — | -1.69% | $119.80 | 44 | $25.97B | Immunology Biotech | Core | |
UTHRUnited Therapeutics Corporation | — | -1.16% | $577.34 | 78 | $24.51B | Rare Disease Biotech | Core | |
INCYIncyte Corporation | — | -1.08% | $117.80 | 71 | $23.88B | Oncology Biotech | Core | |
BNTXBioNTech SE | — | -1.89% | $83.26 | 36 | $20.92B | Vaccines & Infectious Disease | Core | |
ALNYAlnylam Pharmaceuticals, Inc. | — | -4.54% | $149.40 | 16 | $19.95B | Cell & Gene Therapy | Core | |
EXELExelixis, Inc. | — | -0.31% | $68.29 | 93 | $17.17B | Oncology Biotech | Core | |
NBIXNeurocrine Biosciences, Inc. | — | -1.84% | $162.86 | 76 | $16.38B | Neuroscience Biotech | Core | |
JAZZJazz Pharmaceuticals plc | — | +2.93% | $247.77 | 83 | $15.56B | Specialty & Generic Drugs | Core | |
BBIOBridgeBio Pharma, Inc. | — | +1.58% | $78.01 | 70 | $15.28B | Rare Disease Biotech | Core | |
BMRNBioMarin Pharmaceutical Inc. | — | +4.99% | $61.43 | 65 | $11.87B | Rare Disease Biotech | Core | |
KRYSKrystal Biotech, Inc. | — | +5.62% | $315.34 | 77 | $9.3B | Cell & Gene Therapy | Core | |
MDGLMadrigal Pharmaceuticals, Inc. | — | -5.67% | $398.08 | 35 | $9.18B | Metabolic & Cardiovascular Biotech | Core | |
PRAXPraxis Precision Medicines, Inc. | — | +0.04% | $305.19 | 62 | $8.51B | Neuroscience Biotech | Major | |
PCVXVaxcyte, Inc. | — | -1.48% | $58.52 | 72 | $8.45B | Vaccines & Infectious Disease | Major | |
SMMTSummit Therapeutics Inc. | — | -1.59% | $10.50 | 29 | $8.38B | Oncology Biotech | Major | |
PTGXProtagonist Therapeutics, Inc. | — | +2.00% | $127.16 | 84 | $8.18B | Immunology Biotech | Major | |
RYTMRhythm Pharmaceuticals, Inc. | — | +2.08% | $119.04 | 82 | $8.17B | Rare Disease Biotech | Core | |
ALKSAlkermes plc | — | +3.08% | $46.85 | 88 | $7.86B | Specialty & Generic Drugs | Core | |
CORTCorcept Therapeutics Incorporated | — | -3.25% | $67.79 | 66 | $7.28B | Rare Disease Biotech | Core | |
KNSAKiniksa Pharmaceuticals International, plc | — | -0.06% | $95.05 | 96 | $7.24B | Immunology Biotech | Core | |
GRFSGrifols, S.A. | — | -1.85% | $8.47 | 62 | $7.17B | Vaccines & Infectious Disease | Core | |
CGONCG Oncology Inc. | — | +1.34% | $80.00 | 91 | $7.06B | Cell & Gene Therapy | Major | |
IBRXImmunityBio, Inc. | — | +7.03% | $6.70 | 90 | $7.02B | Oncology Biotech | Core | |
AMRXAmneal Pharmaceuticals, Inc. | — | +3.60% | $21.88 | 95 | $6.99B | Specialty & Generic Drugs | Core | |
AXSMAxsome Therapeutics, Inc. | — | -1.43% | $134.00 | 29 | $6.9B | Neuroscience Biotech | Core | |
IMVTImmunovant, Inc. | — | -0.12% | $33.17 | 62 | $6.85B | Immunology Biotech | Major | |
LNTHLantheus Holdings, Inc. | — | +0.20% | $102.00 | 89 | $6.64B | Specialty & Generic Drugs | Core | |
CYTKCytokinetics, Incorporated | — | -0.64% | $51.32 | 28 | $6.39B | Metabolic & Cardiovascular Biotech | Core | |
BLTEBelite Bio, Inc | — | -0.94% | $156.23 | 68 | $6.26B | Ophthalmology Biotech | Major | |
KODKodiak Sciences Inc. | — | +1.04% | $97.81 | 99 | $6.12B | Ophthalmology Biotech | Major | |
ARWRArrowhead Pharmaceuticals, Inc. | — | +0.28% | $43.11 | 25 | $6.07B | Cell & Gene Therapy | Major | |
SRRKScholar Rock Holding Corporation | — | +6.48% | $48.00 | 62 | $5.75B | Rare Disease Biotech | Major | |
MIRMMirum Pharmaceuticals, Inc. | — | +0.59% | $92.49 | 61 | $5.64B | Rare Disease Biotech | Core | |
ABVXAbivax S.A. | — | +2.11% | $83.83 | 28 | $5.5B | Immunology Biotech | Major | |
LQDALiquidia Corporation | — | -0.58% | $56.40 | 85 | $5.02B | Metabolic & Cardiovascular Biotech | Core | |
PTCTPTC Therapeutics, Inc. | — | -0.22% | $60.23 | 41 | $5B | Rare Disease Biotech | Core | |
COGTCogent Biosciences, Inc. | — | -0.14% | $27.81 | 36 | $4.75B | Oncology Biotech | Major | |
TVTXTravere Therapeutics, Inc. | — | -1.68% | $50.24 | 82 | $4.67B | Rare Disease Biotech | Core | |
IONSIonis Pharmaceuticals, Inc. | — | +1.59% | $27.39 | 11 | $4.55B | Cell & Gene Therapy | Core | |
DFTXDefinium Therapeutics, Inc. | — | -0.89% | $29.12 | 93 | $3.91B | Neuroscience Biotech | Major | |
CRSPCRISPR Therapeutics AG | — | +0.10% | $40.19 | 31 | $3.88B | Cell & Gene Therapy | Core | |
OGNOrganon & Co. | — | +0.14% | $13.92 | 91 | $3.66B | Specialty & Generic Drugs | Core | |
XENEXenon Pharmaceuticals Inc. | — | -2.66% | $37.75 | 33 | $3.65B | Neuroscience Biotech | Major | |
INDVIndivior Pharmaceuticals Inc | — | -2.99% | $28.83 | 38 | $3.6B | Specialty & Generic Drugs | Core | |
SUPNSupernus Pharmaceuticals, Inc. | — | -0.28% | $28.96 | 21 | $3.53B | Specialty & Generic Drugs | Core | |
DNTHDianthus Therapeutics, Inc. | — | -3.45% | $83.98 | 87 | $3.51B | Immunology Biotech | Major | |
ARQTArcutis Biotherapeutics, Inc. | — | +1.02% | $27.61 | 76 | $3.45B | Specialty & Generic Drugs | Core | |
IOVAIovance Biotherapeutics, Inc. | — | -0.66% | $7.48 | 97 | $3.34B | Cell & Gene Therapy | Core | |
SLSSELLAS Life Sciences Group, Inc. | — | -6.27% | $17.95 | 99 | $3.34B | Oncology Biotech | Major | |
TARSTarsus Pharmaceuticals, Inc. | — | -2.88% | $75.95 | 74 | $3.27B | Ophthalmology Biotech | Core | |
BHCBausch Health Companies Inc. | — | +3.07% | $8.73 | 93 | $3.26B | Specialty & Generic Drugs | Core | |
ADMAADMA Biologics, Inc. | — | -0.51% | $13.56 | 85 | $3.14B | Vaccines & Infectious Disease | Core | |
ACADACADIA Pharmaceuticals Inc. | — | -2.67% | $17.83 | 29 | $3.05B | Neuroscience Biotech | Core | |
VKTXViking Therapeutics, Inc. | — | -2.64% | $26.17 | 35 | $3.05B | Metabolic & Cardiovascular Biotech | Major | |
TLXTelix Pharmaceuticals Limited | — | +1.13% | $8.96 | 51 | $3.04B | Oncology Biotech | Core | |
LEGNLegend Biotech Corporation | — | +0.87% | $16.25 | 29 | $3.01B | Cell & Gene Therapy | Core | |
VCELVericel Corporation | — | +1.33% | $58.65 | 94 | $3B | Cell & Gene Therapy | Core | |
IRONDisc Medicine, Inc. | — | +1.84% | $77.98 | 69 | $2.98B | Rare Disease Biotech | Major | |
DYNDyne Therapeutics, Inc. | — | -0.94% | $15.87 | 36 | $2.96B | Cell & Gene Therapy | Major | |
AMLXAmylyx Pharmaceuticals, Inc. | — | -3.27% | $26.62 | 93 | $2.96B | Metabolic & Cardiovascular Biotech | Major | |
XERSXeris Biopharma Holdings, Inc. | — | +1.13% | $16.99 | 98 | $2.93B | Rare Disease Biotech | Core | |
DNLIDenali Therapeutics Inc. | — | +2.22% | $18.40 | 45 | $2.92B | Rare Disease Biotech | Major | |
RLAYRelay Therapeutics, Inc. | — | +0.24% | $16.51 | 94 | $2.89B | Oncology Biotech | Major | |
CELCCelcuity Inc. | — | -4.15% | $55.60 | 18 | $2.71B | Oncology Biotech | Major | |
VRDNViridian Therapeutics, Inc. | — | +0.20% | $30.12 | 88 | $2.71B | Immunology Biotech | Core | |
MBXMBX Biosciences, Inc. Common Stock | — | +0.60% | $53.42 | 92 | $2.54B | Rare Disease Biotech | Major | |
ZLABZai Lab Limited | — | -6.03% | $22.11 | 62 | $2.5B | Oncology Biotech | Core | |
HCMHUTCHMED (China) Limited | — | -2.85% | $13.99 | 69 | $2.44B | Oncology Biotech | Core | |
IDYAIDEAYA Biosciences, Inc. | — | -3.32% | $26.49 | 34 | $2.33B | Oncology Biotech | Major | |
NAMSNewAmsterdam Pharma Company N.V. | — | +1.81% | $19.74 | 22 | $2.31B | Metabolic & Cardiovascular Biotech | Major | |
PHVSPharvaris N.V. | — | -2.26% | $31.55 | 67 | $2.2B | Rare Disease Biotech | Major | |
PVLAPalvella Therapeutics, Inc. | — | +1.54% | $146.58 | 92 | $2.1B | Rare Disease Biotech | Major | |
RCUSArcus Biosciences, Inc. | — | -3.84% | $15.76 | 26 | $1.98B | Oncology Biotech | Major | |
AUPHAurinia Pharmaceuticals Inc. | — | -1.75% | $15.13 | 53 | $1.95B | Immunology Biotech | Core | |
BHVNBiohaven Ltd. | — | -2.57% | $12.90 | 85 | $1.94B | Neuroscience Biotech | Major | |
TRVITrevi Therapeutics, Inc. | — | 0.00% | $13.51 | 58 | $1.92B | Neuroscience Biotech | Major | |
HRMYHarmony Biosciences Holdings, Inc. | — | +0.30% | $33.11 | 53 | $1.92B | Neuroscience Biotech | Core | |
ZYMEZymeworks Inc. | — | +0.77% | $26.04 | 68 | $1.92B | Oncology Biotech | Major | |
BCRXBioCryst Pharmaceuticals, Inc. | — | -2.67% | $7.30 | 44 | $1.86B | Rare Disease Biotech | Core | |
VERAVera Therapeutics, Inc. | — | -2.37% | $25.58 | 34 | $1.84B | Immunology Biotech | Major | |
CLDXCelldex Therapeutics, Inc. | — | -1.75% | $27.55 | 47 | $1.83B | Immunology Biotech | Major | |
AGIOAgios Pharmaceuticals, Inc. | — | -0.70% | $29.68 | 47 | $1.77B | Rare Disease Biotech | Core | |
RAREUltragenyx Pharmaceutical Inc. | — | +6.17% | $17.73 | 29 | $1.75B | Rare Disease Biotech | Core | |
ETONEton Pharmaceuticals, Inc. | — | -2.61% | $61.99 | 98 | $1.7B | Rare Disease Biotech | Core | |
ZBIOZenas BioPharma, Inc. | — | -4.79% | $26.42 | 53 | $1.67B | Immunology Biotech | Major | |
REPLReplimune Group, Inc. | — | +0.61% | $19.81 | 98 | $1.66B | Cell & Gene Therapy | Major | |
STOKStoke Therapeutics, Inc. | — | +1.06% | $26.69 | 44 | $1.66B | Cell & Gene Therapy | Major | |
ANIPANI Pharmaceuticals, Inc. | — | +2.11% | $71.47 | 47 | $1.62B | Specialty & Generic Drugs | Core | |
IMNMImmunome, Inc. | — | -2.33% | $16.78 | 31 | $1.6B | Oncology Biotech | Major | |
VIRVir Biotechnology, Inc. | — | -1.08% | $9.15 | 82 | $1.54B | Vaccines & Infectious Disease | Major | |
ALVOAlvotech | — | +4.12% | $4.55 | 73 | $1.54B | Specialty & Generic Drugs | Core | |
SRPTSarepta Therapeutics, Inc. | — | -1.62% | $14.53 | 36 | $1.53B | Cell & Gene Therapy | Core | |
PGENPrecigen, Inc. | — | -0.47% | $4.27 | 36 | $1.52B | Cell & Gene Therapy | Core | |
MESOMesoblast Limited | — | -2.27% | $11.64 | 30 | $1.51B | Cell & Gene Therapy | Core | |
URGNUroGen Pharma Ltd. | — | -0.27% | $29.79 | 57 | $1.45B | Oncology Biotech | Core | |
PCRXPacira BioSciences, Inc. | — | +0.05% | $36.48 | 95 | $1.43B | Specialty & Generic Drugs | Core | |
QUREuniQure N.V. | — | -2.31% | $20.30 | 23 | $1.41B | Cell & Gene Therapy | Major | |
IMCRImmunocore Holdings plc | — | -1.08% | $27.51 | 37 | $1.4B | Oncology Biotech | Core | |
NBTXNanobiotix S.A. | — | -2.00% | $26.90 | 39 | $1.36B | Oncology Biotech | Major | |
INVAInnoviva, Inc. | — | +0.55% | $18.40 | 41 | $1.36B | Specialty & Generic Drugs | Core | |
NUVBNuvation Bio Inc. | — | -3.08% | $3.78 | 28 | $1.31B | Oncology Biotech | Core | |
AMPHAmphastar Pharmaceuticals, Inc. | — | +2.10% | $29.71 | 90 | $1.31B | Specialty & Generic Drugs | Core | |
NVAXNovavax, Inc. | — | 0.00% | $7.96 | 55 | $1.31B | Vaccines & Infectious Disease | Core | |
OCULOcular Therapeutix, Inc. | — | -1.33% | $5.94 | 23 | $1.3B | Ophthalmology Biotech | Major | |
MNKDMannKind Corporation | — | 0.00% | $4.07 | 53 | $1.3B | Specialty & Generic Drugs | Core | |
TSHATaysha Gene Therapies, Inc. | — | -0.25% | $3.99 | 34 | $1.28B | Cell & Gene Therapy | Major | |
NRIXNurix Therapeutics, Inc. | — | -0.98% | $14.10 | 35 | $1.22B | Oncology Biotech | Major | |
MLYSMineralys Therapeutics, Inc. | — | -4.83% | $13.78 | 14 | $1.21B | Metabolic & Cardiovascular Biotech | Major | |
AAPGAscentage Pharma Group International | — | -0.97% | $13.01 | 23 | $1.21B | Oncology Biotech | Core | |
HROWHarrow Health, Inc. | — | +8.94% | $32.16 | 37 | $1.2B | Ophthalmology Biotech | Core | |
NKTRNektar Therapeutics | — | -4.15% | $34.42 | 15 | $1.18B | Immunology Biotech | Major | |
LBRXLB Pharmaceuticals Inc Common Stock | — | -0.60% | $40.06 | 93 | $1.15B | Neuroscience Biotech | Major | |
RAPPRapport Therapeutics, Inc. Common Stock | — | -1.52% | $23.40 | 26 | $1.12B | Neuroscience Biotech | Major | |
NTLAIntellia Therapeutics, Inc. | — | -0.10% | $9.77 | 42 | $1.1B | Cell & Gene Therapy | Major | |
CMPSCOMPASS Pathways plc | — | +1.75% | $8.12 | 45 | $1.1B | Neuroscience Biotech | Major | |
VORVor Biopharma Inc. | — | -1.93% | $17.83 | 81 | $1.06B | Immunology Biotech | Major | |
OMEROmeros Corporation | — | +4.53% | $14.55 | 76 | $1.05B | Immunology Biotech | Core | |
INBXInhibrx Biosciences Inc. | — | -6.90% | $69.06 | 33 | $1.01B | Oncology Biotech | Major | |
GPCRStructure Therapeutics Inc. | — | -4.46% | $17.36 | 10 | $999M | Metabolic & Cardiovascular Biotech | Major | |
SVRASavara Inc. | — | +5.36% | $4.72 | 50 | $967M | Rare Disease Biotech | Major | |
PHARPharming Group N.V. | — | +3.51% | $12.48 | 51 | $932M | Rare Disease Biotech | Core | |
IVAInventiva S.A. | — | +5.28% | $3.39 | 28 | $927M | Metabolic & Cardiovascular Biotech | Major | |
MLTXMoonLake Immunotherapeutics | — | -4.09% | $10.79 | 27 | $908M | Immunology Biotech | Major | |
COLLCollegium Pharmaceutical, Inc. | — | +1.49% | $25.93 | 33 | $841M | Specialty & Generic Drugs | Core | |
RIGLRigel Pharmaceuticals, Inc. | — | -0.91% | $42.53 | 75 | $787M | Immunology Biotech | Core | |
IRWDIronwood Pharmaceuticals, Inc. | — | -1.85% | $4.78 | 85 | $787M | Specialty & Generic Drugs | Core | |
ARDXArdelyx, Inc. | — | -1.89% | $3.12 | 22 | $771M | Specialty & Generic Drugs | Core | |
SNDXSyndax Pharmaceuticals, Inc. | — | -6.96% | $8.56 | 13 | $759M | Oncology Biotech | Core | |
DCTHDelcath Systems, Inc. | — | +1.70% | $19.70 | 96 | $680M | Oncology Biotech | Core | |
KURAKura Oncology, Inc. | — | -2.00% | $7.34 | 28 | $652M | Oncology Biotech | Core | |
GERNGeron Corporation | — | -0.91% | $0.99 | 28 | $636M | Oncology Biotech | Core | |
VSTMVerastem, Inc. | — | -7.29% | $6.87 | 77 | $604M | Oncology Biotech | Core | |
ZVRAZevra Therapeutics, Inc. | — | -1.28% | $9.28 | 47 | $549M | Rare Disease Biotech | Core | |
VALNValneva SE | — | -4.13% | $5.34 | 30 | $506M | Vaccines & Infectious Disease | Core | |
EOLSEvolus, Inc. | — | +5.68% | $7.07 | 72 | $466M | Specialty & Generic Drugs | Core | |
KMDAKamada Ltd. | — | -1.10% | $8.07 | 66 | $466M | Vaccines & Infectious Disease | Core | |
FENCFennec Pharmaceuticals Inc. | — | -1.84% | $13.33 | 91 | $463M | Oncology Biotech | Core | |
HELPHelus Pharma Inc. | — | -4.31% | $6.89 | 56 | $427M | Neuroscience Biotech | Major | |
PHATPhathom Pharmaceuticals, Inc. | — | -3.64% | $5.30 | 15 | $423M | Specialty & Generic Drugs | Core | |
GYREGyre Therapeutics, Inc. | — | -4.82% | $4.34 | 21 | $397M | Immunology Biotech | Core | |
PBYIPuma Biotechnology, Inc. | — | +1.12% | $7.22 | 65 | $367M | Oncology Biotech | Core | |
SPRYARS Pharmaceuticals, Inc. | — | +1.10% | $3.69 | 17 | $366M | Immunology Biotech | Core | |
CRMDCorMedix Inc. | — | -3.64% | $4.50 | 18 | $353M | Vaccines & Infectious Disease | Core | |
EBSEmergent BioSolutions Inc. | — | -1.96% | $5.50 | 37 | $284M | Vaccines & Infectious Disease | Core | |
AUTLAutolus Therapeutics plc | — | -2.75% | $1.06 | 20 | $282M | Cell & Gene Therapy | Core | |
PLXProtalix BioTherapeutics, Inc. | — | +4.86% | $3.02 | 90 | $243M | Rare Disease Biotech | Core | |
AMRNAmarin Corporation plc | — | -0.09% | $11.26 | 33 | $234M | Metabolic & Cardiovascular Biotech | Core | |
VNDAVanda Pharmaceuticals Inc. | — | -1.57% | $3.75 | 28 | $226M | Neuroscience Biotech | Core | |
SIGASIGA Technologies, Inc. | — | +2.56% | $2.80 | 27 | $201M | Vaccines & Infectious Disease | Core | |
MDWDMediWound Ltd. | — | -0.51% | $13.61 | 45 | $175M | Specialty & Generic Drugs | Core | |
ADCTADC Therapeutics S.A. | — | +1.48% | $1.37 | 36 | $174M | Oncology Biotech | Core | |
ABEOAbeona Therapeutics Inc. | — | +5.00% | $2.73 | 16 | $156M | Cell & Gene Therapy | Core | |
IVVDInvivyd, Inc. | — | -8.21% | $0.47 | 10 | $139M | Vaccines & Infectious Disease | Core | |
ACOGAlpha Cognition Inc | — | +8.59% | $8.60 | 87 | $134M | Neuroscience Biotech | Core | |
AKBAAkebia Therapeutics, Inc. | — | +2.12% | $0.41 | 10 | $110M | Metabolic & Cardiovascular Biotech | Core | |
DERMJourney Medical Corporation | — | -5.38% | $3.69 | 15 | $102M | Specialty & Generic Drugs | Core | |
LENZLENZ Therapeutics, Inc. | — | -8.29% | $3.21 | 13 | $101M | Ophthalmology Biotech | Core | |
FBIOFortress Biotech, Inc. | — | +3.85% | $1.89 | 26 | $63M | Specialty & Generic Drugs | Core | |
HRTXHeron Therapeutics, Inc. | — | -3.26% | $0.27 | 16 | $52M | Specialty & Generic Drugs | Core | |
CTORCitius Oncology, Inc. | — | +0.44% | $0.55 | 21 | $51M | Oncology Biotech | Core | |
CHRSCoherus Oncology, Inc. | — | -14.34% | $0.41 | 7 | $50M | Oncology Biotech | Core | |
TNXPTonix Pharmaceuticals Holding Corp. | — | -4.08% | $2.82 | 3 | $45M | Neuroscience Biotech | Core | |
PTHSPelthos Therapeutics Inc. | — | +3.80% | $7.10 | 5 | $25M | Specialty & Generic Drugs | Core | |
AYTUAytu BioPharma, Inc. | — | 0.00% | $2.66 | 85 | $22M | Specialty & Generic Drugs | Core | |
BFRIBiofrontera Inc. | — | +1.10% | $0.60 | 20 | $8M | Specialty & Generic Drugs | Core | |
SCLXScilex Holding Company | — | -2.29% | $0.63 | 1 | $5M | Specialty & Generic Drugs | Core | |
KPTIKaryopharm Therapeutics Inc. | — | -0.39% | $0.03 | 1 | $575639 | Oncology Biotech | Core | |
JAGXJaguar Health, Inc. | — | -7.03% | $0.35 | 1 | $19052 | Specialty & Generic Drugs | Core |
Biotech & Healthcare Stocks -16.3%SPY -5.1%
Equal-weight return of the theme's stocks from the range start, against SPY. Daily market data.
| Window | Theme | SPY | vs SPY |
|---|---|---|---|
| Today | -0.7% | -0.3% | -0.4% |
| 5D | -4.3% | -3.6% | -0.8% |
| 1M | -2.7% | -4.7% | +2.0% |
| 3M | -16.3% | -5.1% | -11.2% |
| 6M | +6.9% | -0.5% | +7.4% |
| YTD | +9.5% | +7.1% | +2.5% |
| 1Y | +22.0% | +10.2% | +11.8% |
Large-cap pharma, gene editing, medical devices, life sciences tools, and AI-driven drug discovery across the healthcare stack.
US biotech and healthcare stocks screened by market data, analyst coverage, and pipeline depth — large-cap pharma, gene therapy, medical devices, and AI-driven drug discovery.
195 US-listed stocks, placed in this theme by our own classification of each company's business. Setups come from the same chart-pattern engine as the breakout page and update after the close.
This page covers the full life sciences spectrum, from GLP-1 blockbusters to early gene editing platforms.
Biotech and healthcare investing spans a wide risk spectrum. Large-cap pharma like LLY and NVO generates predictable cash flows from patent-protected blockbusters; clinical-stage gene editors trade almost entirely on pipeline optionality. Medical device leaders like ISRG and DXCM sit closer to SaaS in revenue predictability; tools companies like TMO and DHR are industrial-style compounders with sticky consumable revenue. All qualify when healthcare demand materially drives the investment thesis.
Revenue growth, R&D intensity, and pipeline stage are the key inputs — not just P/E ratios.
Pharma and large-cap biotech trade on earnings and pipeline optionality — a low P/E can still be expensive if a key patent expires in two years. Clinical-stage biotechs are valued on pipeline probability: Phase 3 timeline, estimated peak sales, and the market's implied success rate. Devices and tools companies trade more like SaaS — compare revenue growth, recurring revenue mix, and operating leverage. Use the screener to compare growth rates, margins, and EV/Sales side by side.
Patent cliffs, trial failures, and pricing pressure are the three largest structural risks.
Patent expirations are existential for large pharma: when a blockbuster loses exclusivity, revenue can fall 80% within 18 months. For clinical-stage biotechs, Phase 3 failure wipes most of the equity value in a single session. Managed care faces reimbursement regulation risk; tools companies are cyclically sensitive to biotech funding environments. Understanding which risk profile applies to each sub-sector is essential before sizing.
Companies whose revenue is materially driven by pharmaceutical development and commercialization, medical device sales, life sciences tools and instrumentation, managed care enrollment, or AI-driven drug discovery. Spans a wide risk spectrum from defensive large-cap pharma (LLY, ABBV) to clinical-stage gene editing pure-plays (CRSP, NTLA).
Eli Lilly (LLY) and Novo Nordisk (NVO) dominate GLP-1 / obesity — the largest growth driver in pharma. Vertex (VRTX) has a unique CF franchise and emerging pipeline in pain and kidney disease. Regeneron (REGN) commands ophthalmology and has a strong oncology pipeline. CRISPR Therapeutics (CRSP) leads gene editing with sickle cell approval. The best entry point depends on tolerance for pipeline risk.
The distinction is blurring. Traditional pharma (Merck, Pfizer) has diversified commercial portfolios and distributes significant dividends. Large-cap biotech (Amgen, Gilead) operates similarly but may be more concentrated. Small-cap biotech usually refers to pre-revenue or early-commercial companies where the entire value is in pipeline probability. The screener labels all three under a single theme for unified comparison.
Large-cap pharma and managed care are relatively defensive — healthcare spending is inelastic and insurance enrollment is sticky. However, biotech and medical devices are growth-oriented and can underperform in risk-off environments. Drug pricing legislation is a macro-level risk that affects the entire sector. Defensiveness decreases significantly as you move from managed care to clinical-stage biotech.
GLP-1 agonists (Ozempic, Wegovy, Mounjaro) represent the largest drug class inflection in decades. Key beneficiaries: LLY and NVO as direct producers; device makers could face headwinds if obesity reduces surgical volume; managed care faces near-term cost pressure but long-term savings from reduced co-morbidities. Scale and manufacturing capacity have become the new moat.